In 1192 patients with autoimmune rheumatic diseases on immunosuppression, recombinant zoster vaccine was non-inferior to placebo for flare to day 84 (14% vs 15%). Adverse events were more frequent with vaccine (77% vs 31% after dose 1).
RCTn = 1,192
Aikawa et al. Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study